Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract that includes Crohn’s disease and ulcerative colitis. Research shows that IBD arises from a complex interaction between genetic susceptibility, the immune system, gut microbes and environmental factors.

Large genetic studies have identified many risk genes involved in immune regulation, barrier function and microbial sensing. However, genes alone are not sufficient to cause disease. Environmental influences such as urban living, diet low in fiber and high in fat, smoking, antibiotic exposure and early life events appear to modify risk and may help explain the rising incidence of IBD worldwide, especially in newly industrialized regions.

The intestinal barrier and mucus layer are central in disease development. When this barrier is compromised, microbial products can cross into the tissue, triggering persistent immune activation. Research highlights the importance of innate immune cells and cytokines like TNF, IL 23 and IL 6, as well as adaptive T helper cell subsets, in sustaining chronic inflammation.

The gut microbiome is consistently altered in IBD. Patients tend to have reduced microbial diversity and a loss of beneficial species that produce anti inflammatory metabolites such as short chain fatty acids, along with an expansion of potentially harmful bacteria. This dysbiosis may both result from and drive inflammation.

Current therapies target key inflammatory pathways, including biologics against TNF, integrins and IL 12 or IL 23, as well as small molecules modulating intracellular signaling. Research is moving toward precision medicine, integrating genetic, microbial and immune profiles to predict disease course and guide individualized treatment.